



Multimeric

Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics announces issuance of Japan patent for the MegaLigands™

September 25, 2012, La Jolla, CA –Multimeric Biotherapeutics, Inc. (“Multimeric”), an innovative vaccine company based in San Diego, announced the issuance in Japan of a patent for the MegaLigands™, Japanese patent # 5031165. This patent is part of the family derived from the PCT filing WO 2001/049866. Other patents based on this filing have already issued in Europe (with validation in 20 European countries), China, Israel, Korea, Singapore, and South Africa. Patent applications are pending in Brazil, Canada, and Hungary.

Multimeric previously announced on October 28, 2011 that it exclusively licensed these patents and applications from Topotarget A/S (NASDAQ OMX: TOPO.CO). However, Topotarget retains its rights to MegaFasL™ (APO010), a drug that has been in clinical trials for cancer.

About the MegaLigands™: The term MegaLigands™ refers to 2-trimer forms of the TNFSF ligands produced by fusing the extracellular domains of any of the 19 members of the TNF SuperFamily with a scaffold protein consisting of the body of ACRP30 (adiponectin). The following molecules are currently sold by third parties as purified proteins for laboratory use: MegaCD40L™; MegaTNF™; MegaOX40L™; and MegaAPRIL™. MegaCD40L™ in particular has been used extensively by academic investigators as a vaccine adjuvant and cancer immunotherapy agent.

About the UltraLigands™: The term UltraLigands™ refers to 4-trimer forms of the TNFSF ligands produced by fusing the extracellular domains of any of the 19 members of the TNF SuperFamily with a scaffold protein consisting of the body of surfactant protein D (SP-D). UltraCD40L™ has been shown to be a powerful adjuvant for DNA vaccines as well as an effective cancer immunotherapy in mouse models. A recently published study in the journal *Vaccine* demonstrated the versatility of this platform technology by reporting applications for the following UltraLigands™ as adjuvants for DNA vaccines: UltraCD40L™; UltraGITRL™; Ultra4-1BBL™; UltraOX40L™; UltraRANKL™; UltraLIGHT™; UltraCD70™; and UltraBAFF™.

About Multimeric: Multimeric Biotherapeutics, Inc., a Delaware C corporation, was spun out of technology developed by Dr. Richard Kornbluth when he was at the University of California San Diego. Multimeric’s lead products include immunotherapy protocols for cancer and vaccines against chronic viral infections. The company is privately held and is supported by its founders, angel investors, and NIH grants. It has offices in La Jolla, CA and laboratories at the San Diego Science Center in San Diego, CA. For more information, please refer to www.multimericbio.com